PARP1 and glioblastoma: Although our data do not strongly support a causative link between HMGA2 and NAD+ metabolism, an important role for NAMPT in providing NAD+ substrate for PARP catalytic activity was recently shown as NAMPT inhibition by FK866 enhanced the effectiveness of olaparib treatment in triple‐negative breast cancer xenografts (Bajrami et al., 2012) and increased cytotoxicity of temozolomide in combination with BER inhibition in glioblastoma (Goellner et al., 2011).